Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis
Background. The long-term prognosis after curative therapy for hepatitis B virus- (HBV-) related hepatocellular carcinoma (HCC) remains unsatisfactory due to the high incidence of recurrence. The effect of treatment with nucleotide analogues (NAs) in patients with HBV-related HCC after curative ther...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2016/5234969 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850230131179651072 |
|---|---|
| author | Peng Yuan Peng Chen Yeben Qian |
| author_facet | Peng Yuan Peng Chen Yeben Qian |
| author_sort | Peng Yuan |
| collection | DOAJ |
| description | Background. The long-term prognosis after curative therapy for hepatitis B virus- (HBV-) related hepatocellular carcinoma (HCC) remains unsatisfactory due to the high incidence of recurrence. The effect of treatment with nucleotide analogues (NAs) in patients with HBV-related HCC after curative therapy remains unclear. Objective. To assess the impact of using NAs after curative therapy. Method. A computerized literature search was performed; eligible studies were identified from databases. The pooled risk ratios (RRs) and 95% CIs were calculated using Review Manager 5.3. Result. The meta-analysis included a total of 15 studies with 8060 patients. The one-year and three-year recurrence (one-year recurrence: RR 0.41 [95% CI 0.28 to 0.61]; P<0.00001; three-year recurrence: RR 0.63 [95% CI 0.43 to 0.94]; P=0.001) and the one-, three-, and five-year overall survival (OS) and disease-free survival (DFS) were significantly better in the treatment group. Conclusion. NAs can reduce the recurrence and improve the prognosis of HBV-related HCC after curative therapy. |
| format | Article |
| id | doaj-art-2a09bf41f67e48d1b9a5a4c7e9e36a1e |
| institution | OA Journals |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-2a09bf41f67e48d1b9a5a4c7e9e36a1e2025-08-20T02:03:58ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972016-01-01201610.1155/2016/52349695234969Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-AnalysisPeng Yuan0Peng Chen1Yeben Qian2Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, ChinaDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, ChinaDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, ChinaBackground. The long-term prognosis after curative therapy for hepatitis B virus- (HBV-) related hepatocellular carcinoma (HCC) remains unsatisfactory due to the high incidence of recurrence. The effect of treatment with nucleotide analogues (NAs) in patients with HBV-related HCC after curative therapy remains unclear. Objective. To assess the impact of using NAs after curative therapy. Method. A computerized literature search was performed; eligible studies were identified from databases. The pooled risk ratios (RRs) and 95% CIs were calculated using Review Manager 5.3. Result. The meta-analysis included a total of 15 studies with 8060 patients. The one-year and three-year recurrence (one-year recurrence: RR 0.41 [95% CI 0.28 to 0.61]; P<0.00001; three-year recurrence: RR 0.63 [95% CI 0.43 to 0.94]; P=0.001) and the one-, three-, and five-year overall survival (OS) and disease-free survival (DFS) were significantly better in the treatment group. Conclusion. NAs can reduce the recurrence and improve the prognosis of HBV-related HCC after curative therapy.http://dx.doi.org/10.1155/2016/5234969 |
| spellingShingle | Peng Yuan Peng Chen Yeben Qian Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis Canadian Journal of Gastroenterology and Hepatology |
| title | Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_full | Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_fullStr | Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_full_unstemmed | Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_short | Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_sort | evaluation of antiviral therapy performed after curative therapy in patients with hbv related hepatocellular carcinoma an updated meta analysis |
| url | http://dx.doi.org/10.1155/2016/5234969 |
| work_keys_str_mv | AT pengyuan evaluationofantiviraltherapyperformedaftercurativetherapyinpatientswithhbvrelatedhepatocellularcarcinomaanupdatedmetaanalysis AT pengchen evaluationofantiviraltherapyperformedaftercurativetherapyinpatientswithhbvrelatedhepatocellularcarcinomaanupdatedmetaanalysis AT yebenqian evaluationofantiviraltherapyperformedaftercurativetherapyinpatientswithhbvrelatedhepatocellularcarcinomaanupdatedmetaanalysis |